Variable | Study group (n = 54) |
---|---|
Men, n (%) | 41 (75.9) |
Age (years), mean ± SD | 59.5 ± 8.6 |
SBP (mmHg), mean ± SD | 133.4 ± 18.6 |
DBP (mmHg), mean ± SD | 77.5 ± 11.1 |
HR (bpm), mean ± SD | 66.8 ± 11.9 |
BMI (kg/m2), mean ± SD | 28.3 ± 4.1 |
Creatinine (mg/dL), mean ± SD | 0.92 ± 0.20 |
eGFR < 60 mL/min/1.73 m2, n (%) | 3 (5.6) |
LVEF (%), mean ± SD | 54.5 ± 7.8 |
LVEF < 50%,, n (%) | 11 (20.4) |
HFpEF, n (%) | 3 (5.6) |
HFmrEF, n (%) | 4 (7.4) |
HFrEF, n (%) | 5 (9.3) |
Hypertension, n (%) | 39 (72.2) |
Diabetes, n (%) | 11 (20.4) |
hypercholesterolemia, n (%) | 45 (83.3) |
COPD, n (%) | 3 (5.6) |
Atrial fibrillation paroxysmal in medical history, n (%) | 5 (9.3)/0 (0.0) |
Smoking, n (%) | 29 (53.7) |
Symptoms | |
Reduced exercise tolerance, n (%) | 25 (46.5) |
Dyspnea during exercise, n (%) | 14 (25.9) |
Dyspnea at rest, n (%) | 3 (5.6) |
Pharmacotherapy | |
ACEI, n (%) | 53 (98.2) |
ARB, n (%) | 1 (1.9) |
BB, n (%) | 51 (94.4) |
Diuretic, n (%) | 20 (37.0) |
CB, n (%) | 11 (20.4) |
MRA, n (%) | 3 (5.6) |
Statin, n (%) | 53 (98.2) |
Antiplatelet, n (%) | 54 (100) |